Ultrasound-Guided Transbronchial Needle-Delivered Interstitial Photodynamic Therapy for Lung Cancer
Study Summary
This trial is testing a new cancer treatment that uses light to kill cancer cells.
- Lung Cancer
- Stage III Lung Cancer
- Stage IIIA Lung Cancer
- Stage IIIB Lung Cancer
- Small Cell Lung Cancer
- Non-Small Cell Lung Cancer
Treatment Effectiveness
Effectiveness Progress
Study Objectives
2 Primary · 1 Secondary · Reporting Duration: Up to 24 weeks
Trial Safety
Safety Progress
Trial Design
1 Treatment Group
Treatment (porfimer sodium, EBUS, and photodynamic therapy)
1 of 1
Experimental Treatment
36 Total Participants · 1 Treatment Group
Primary Treatment: Ultrasound-Guided Transbronchial Needle-Delivered Interstitial Photodynamic Therapy · No Placebo Group · Phase 1 & 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 6 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
What has been observed in prior research on Ultrasound-Guided Transbronchial Needle-Delivered Interstitial Photodynamic Therapy?
"Currently, there are 5 ongoing clinical trials exploring Ultrasound-Guided Transbronchial Needle-Delivered Interstitial Photodynamic Therapy. None of these studies have yet reached Phase 3; however, they can be found in 6 different locations around Buffalo, New York." - Anonymous Online Contributor
Are there any current opportunities to sign up for this research endeavor?
"According to the clinicaltrials.gov listing, this research initiative is actively looking for volunteers; it was first posted in February 12th 2020 with a subsequent update occurring on May 31st 2022." - Anonymous Online Contributor
What is the aggregate number of participants enrolled in this research project?
"Affirmative. Clinicaltrials.gov conveys that this medical research is seeking participants, which was originally announced on 2/12/2020 and most recently revised on 5/31/2022. This study requires 36 patients to be enrolled from one site." - Anonymous Online Contributor